Viatris Swats Away Concerns Over Divestment Valuations

As US-Based Firm Updates On Glatiramer And Botox Biosimilar

 
• By Dean Rudge
Dollars (David Wall/Alamy Stock Photo)
Rising rates are no concern to Viatris currently • Source: Shutterstock (Alamy Stock Photo)

More from Strategy

More from Business